MedPath

Early Detection of COVID-19 Using Breath Analysis

Not Applicable
Completed
Conditions
Covid19
Registration Number
NCT04602884
Lead Sponsor
Scentech Medical Technologies Ltd
Brief Summary

EARLY DETECTION OF COVID-19 USING BREATH ANALYSIS- FIRST CROSS-SECTIONAL STUDY

Detailed Description

Primary objective- to identify and evaluate a set of biomarkers that represent both the genetic expression of the virus itself (SARS-CoV-2) and the metabolic activity of the immune system's response to the virus.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Age 18 to 55 years at the time of consent
  • Positive results for SARS-CoV-2
  • Capable of understanding written and/or spoken language
  • Able to provide informed consent
Exclusion Criteria
  • Age under 18 years old
  • (Anticipated) inability to complete breath sampling procedure due to e.g. hyper- or hypoventilation, respiratory failure, or claustrophobia when wearing the sampling mask
  • Persons under guardianship or deprived of liberty
  • Patients with the following diseases: Cancer, Asthma, Chronic Respiratory Disease
  • Pregnant women
  • Treated with antiviral drugs upon admission or during hospitalization
  • Novices and soldiers in initial training

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Correlation between Volatile Organic Compounds pattern and COVID-19 detection status.Through the study completion, up to 3 months.

Correlation between the set of Volatile Organic Compounds found in breath biopsy and COVID-19 detection presence in a swab test.

Secondary Outcome Measures
NameTimeMethod
Correlation between Volatile Organic Compounds pattern and time from COVID-19 detection.Through the study completion, up to 3 months.

Correlation between the set of Volatile Organic Compounds found in breath biopsy and time since COVID-19 detected in a swab test.

Correlation between the set of Volatile Organic Compounds found in breath biopsy and disease intensity.Through the study completion, up to 3 months.

Correlation between the set of Volatile Organic Compounds found in breath biopsy and intensity of COVID-19 detected in a swab test.

Trial Locations

Locations (1)

IDF COVID 19 Isolation Facility

🇮🇱

Ashkelon, Israel

IDF COVID 19 Isolation Facility
🇮🇱Ashkelon, Israel

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.